1. Service Overview
We deliver GMP, FDA and EU GMP-compliant specialized facility design and high-level containment solutions tailored for Antibody-drug Conjugate (ADC) manufacturing, covering full-process plant planning for ADC linker-payload synthesis, conjugation reaction, purification, sterile filling and hazardous waste disposal. Targeting the dual characteristics of biologic sterility requirements and small-molecule cytotoxic hazard risks of ADC products, our design services focus on high-grade biosafety isolation, cytotoxic cross-contamination prevention, personnel protection and environmental emission control. We solve critical industry pain points such as insufficient hazardous material containment, conflicting sterile and safety design logic, and incomplete risk isolation in traditional pharmaceutical plants, providing audit-ready, high-safety and fully standardized facility solutions for global ADC biotech firms, oncologic pharmaceutical manufacturers and professional CDMO platforms.
2. Core Service Scope & Technical Specifications
Our full-spectrum ADC facility design portfolio covers systematic containment planning, functional zoning optimization and customized technical deployment for high-risk targeted drug production. The core scope includes independent negative-pressure containment zone partitioning, sterile and cytotoxic dual-standard space design, and physical isolation layout for low-dose highly toxic payload processing and antibody conjugation workshops. We deliver targeted engineering schemes for high-efficiency exhaust filtration systems, closed material transfer and fully enclosed production skid layout, dedicated personnel disinfection and changing passages, and classified hazardous waste collection and treatment systems. All design configurations adopt hierarchical pressure gradient control, zero-leakage structural layout and independent air circulation system, fully complying with international ADC manufacturing containment guidelines and GMP sterile production specifications to achieve zero cross-contamination and controllable hazardous risk exposure.
3. Technical & Quality Advantages
Differentiated from conventional biopharmaceutical and high-potency drug plant design, our ADC facility solutions adopt dual-core design logic integrating sterile biomanufacturing and cytotoxic hazard containment, exclusively optimized for the unique production attributes of ADC conjugate reactions. We embed full-link risk control mechanisms including toxic dust isolation, residual drug containment, microbial sterility assurance and dynamic environmental monitoring in the initial design phase, fundamentally eliminating core risks such as product contamination, personnel exposure and environmental leakage. The entire design process implements standardized safety verification, parameter calibration and full-document traceability, with complete containment assessment reports and GMP compliance documents. All design outcomes conform to global ADC industrial best practices, ensuring seamless compatibility with international safety inspections and pharmaceutical regulatory audits.
4. Industrial Value & Delivery Commitment
Our professional ADC containment and facility design enables pharmaceutical enterprises to build internationally compliant, high-safety production platforms for high-value targeted anticancer drugs. Scientific dual-standard layout effectively resolves the conflict between sterile production and hazardous safety management, greatly reducing operational safety risks, batch failure rates and regulatory rectification costs. Standardized modular design supports flexible production switching and future pipeline expansion, maximizing long-term plant utilization. We provide one-stop full-cycle technical support including customized scheme optimization, safety compliance consultation, complete document delivery and on-site engineering guidance. With in-depth mastery of ADC production characteristics and global pharmaceutical regulatory standards, we help clients accelerate ADC product industrialization and global market access, consolidating core competitive advantages in the precision biopharmaceutical sector.
